Everence Capital Management Inc. Acquires 6,770 Shares of Boston Scientific Co. (NYSE:BSX)

Everence Capital Management Inc. lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 15.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 49,660 shares of the medical equipment provider’s stock after purchasing an additional 6,770 shares during the period. Everence Capital Management Inc.’s holdings in Boston Scientific were worth $4,436,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Boston Scientific by 4.4% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider’s stock valued at $345,205,000 after buying an additional 173,034 shares during the last quarter. HWG Holdings LP bought a new position in Boston Scientific during the 2nd quarter worth approximately $482,000. Principal Financial Group Inc. lifted its position in Boston Scientific by 5.9% in the third quarter. Principal Financial Group Inc. now owns 2,010,441 shares of the medical equipment provider’s stock valued at $168,475,000 after purchasing an additional 111,724 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Boston Scientific by 0.9% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,456,741 shares of the medical equipment provider’s stock valued at $289,675,000 after purchasing an additional 30,636 shares during the period. Finally, Intech Investment Management LLC grew its holdings in shares of Boston Scientific by 153.5% in the third quarter. Intech Investment Management LLC now owns 197,387 shares of the medical equipment provider’s stock worth $16,541,000 after purchasing an additional 119,525 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney sold 162,777 shares of Boston Scientific stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the sale, the chief executive officer now directly owns 1,572,096 shares in the company, valued at $133,046,484.48. The trade was a 9.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the transaction, the executive vice president now owns 160,467 shares in the company, valued at approximately $13,639,695. This trade represents a 45.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 321,174 shares of company stock worth $27,372,081 in the last three months. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 1.6 %

Shares of NYSE BSX traded up $1.42 during trading on Friday, reaching $90.80. The company had a trading volume of 840,079 shares, compared to its average volume of 2,053,965. The business’s 50-day moving average is $88.86 and its 200 day moving average is $83.10. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The stock has a market cap of $133.82 billion, a PE ratio of 75.04, a P/E/G ratio of 2.67 and a beta of 0.80. Boston Scientific Co. has a 12-month low of $57.58 and a 12-month high of $91.93.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The business had revenue of $4.21 billion during the quarter, compared to analysts’ expectations of $4.04 billion. During the same period in the previous year, the company earned $0.50 earnings per share. The business’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, equities analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BSX has been the subject of several analyst reports. Royal Bank of Canada increased their price target on shares of Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. TD Cowen increased their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, December 12th. Stifel Nicolaus boosted their price target on Boston Scientific from $85.00 to $100.00 and gave the company a “buy” rating in a report on Friday, October 18th. Bank of America increased their price objective on Boston Scientific from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. Finally, Citigroup boosted their target price on Boston Scientific from $98.00 to $107.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $95.96.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.